Emcitate (tiratricol)

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

23 evidence topics · 8 sources